Literature DB >> 3497884

Lysis of tumor cells by the retargeting of murine cytolytic T lymphocytes with bispecific antibodies.

I G Barr, H R MacDonald, F Buchegger, V von Fliedner.   

Abstract

The specificity and efficiency of tumor-cell lysis by the retargeting of murine cytolytic lymphocytes (CTL) with bispecific antibodies was examined. Bispecific antibodies (also known as heteroaggregated or hybrid antibodies) were produced by the chemical coupling of monoclonal antibodies (MAbs) against H-2 antigens and the murine T-cell receptor (TCR). Murine tumor cell lines which expressed on their plasma membrane an antigen reactive with one component of the bispecific antibody were efficiently lysed in the presence of polyclonal murine CTL. CTL capable of lysis were generated by stimulating spleen or lymph-node cells with ConA and IL-2, while unstimulated cells or cells incubated only with IL-2 showed no lysis of target cells with bispecific antibodies. Furthermore, the lysis of target cells by bispecific antibodies and CTL did not cause the lysis of bystander cells (cells not expressing an antigen recognized by the antibody which are mixed with the target cells). The efficient CTL-mediated lysis observed with these antibodies makes this a promising approach for the immunotherapy of human cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497884     DOI: 10.1002/ijc.2910400323

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

Review 1.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.

Authors:  P D Foglesong; M A Winkler; J O Price; G D Marshall; S H Reagh; D A Bush; K S Hixson; W H West
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

4.  Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).

Authors:  I A Haagen; R van de Griend; M Clark; A Geerars; B Bast; B de Gast
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.